For example, NSCLC patients with PD-L1 tumor proportion score (TPS) ≥ 50% seem to benefit from immunotherapy, but for those carrying EGFR-sensitive mutations and ALK rearrangements (EGFR+/ALK+), the response to immunotherapy appears to be poor. The gene discussed is ALK; the disease is non-small cell lung carcinoma.